Clinical Ink: lupus studies deserve a better approach
One company leader says systemic lupus erythematosus clinical trials require increased understanding and more efficient data collection.
One company leader says systemic lupus erythematosus clinical trials require increased understanding and more efficient data collection.
The two firms are joining forces to develop AI-based technology for continuous manufacturing of critical APIs necessary for producing crucial small-molecule drugs.
The technology offers data analytics capabilities specific to the research and development of therapies targeted at the virus.
Paid for and in partnership with Merck KGaA, Darmstadt, Germany
Industry pipelines and portfolios have changed significantly, in recent years, with the small molecules that used to dominate increasingly giving way to biologics.